GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2021-04-22| Asia-PacificCOVID-19

Singapore’s Prestige Biopharma Prepares for Global Vaccine Deals, Constructs Global Vaccine Center in South Korea

by Tyler Chen
Share To

Image Courtesy: Business Wire

The COVID-19 pandemic has propelled global vaccine development as supply chains have stepped up their game in production capacity and uptime. Singapore-based Prestige Biopharma (PBP), which mainly focuses on antibody R&D, plans to add vaccine development and production to their core business. The company wants to initiate Russia’s Sputnik V vaccine production in Korea as early as August.

Vaccine Center in South Korea

PBP began construction of a vaccine production center in Osong, South Korea, in March to meet the global demands. The facility is expected to finish system validation and operate as soon as August and reach full production by the end of 2021.

The plant will include 50 units of 2,000 litre single-use bioreactors with accompanying seed train and downstream purification capacities, which accounts for a total capacity of 100,000 litres. What’s more, it will adopt the world’s first smart AI factory system in biomanufacturing designed to maximize the outcome and minimize the cost and human error.

Assistance in Vaccine Manufacturing

In April, PBP joined a consortium led by Korean biotech firm Huons Global to help manufacture Sputnik V in South Korea, and the vaccine center is going to play a big part in the plan. In addition to the COVID-19 vaccines, the facility will support and develop vaccines for infectious diseases in the future.

Related Article: Singapore Targets Widespread Implementation of Precision Medicine, Launches Phase II of its 10-Year Plan

 

 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
AstraZeneca’s $1.5 Billion ADC Manufacturing Facility in Singapore
2024-05-23
R&D
Breakthrough Screening Platform to Assess SARS-CoV-2 Mutations and Potential Treatments
2024-04-16
AbbVie Boosts Global Manufacturing with $223 Million Expansion in Singapore
2024-01-29
LATEST
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
The Fallout of the USAID Funding Freeze: Implications for Global Health and Biopharmaceutical Innovation
2025-02-11
Trump’s Trade War Shake-Up: How U.S. Tariffs Could Disrupt Global Pharma
2025-02-10
Precision Medicine Market Skyrocketing, Shaking the Industry with $470.53 Billion Expected by 2034
2025-02-10
Super Bowl LIX and the Biotech Sector: A New Arena for Engagement
2025-02-09
What the PlayStation Network Outage Can Teach the Biotech Industry
2025-02-08
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
Scroll to Top